Anabolic interventions in ESRD: light at the end of the tunnel?
Hakim
Raymond M
RM
Ikizler
T Alp
TA
D054439:Ghrelin / Q000627:therapeutic use; D006801:Humans; D007211:Indoles / Q000627:therapeutic use*; D007676:Kidney Failure, Chronic / Q000150:complications / Q000188:drug therapy* / Q000378:metabolism*; D008659:Metabolic Diseases / Q000188:drug therapy / Q000209:etiology; D013141:Spiro Compounds / Q000627:therapeutic use*
D054439:Ghrelin; D007211:Indoles; D013141:Spiro Compounds; C094817:ibutamoren mesylate